AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...

The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and ...

Kaerus Bioscience has received US Food and Drug Administration’s (FDA) designations for KER-0193 to treat Fragile X syndrome ...

A new specialist manufacturing facility in Scotland could soon provide solutions to scaling challenges for vital ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

HLS Therapeutics has signed an agreement with Esperion Therapeutics for in-licensing and commercialising the oral ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease ...